mRNA-1443 / Moderna - LARVOL DELTA

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults (clinicaltrials.gov) - P1; N=181; Completed; Sponsor: ModernaTX, Inc.; Active, not recruiting ➔ Completed; Trial completion date: Jul 2020 ➔ Oct 2020; Trial primary completion date: Jul 2020 ➔ Oct 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Cytomegalovirus Infection • Infectious Disease • IFNG